The approval of two kinase-targeting drugs, Genentech's trastuzumab (Herceptin®) in 1998 and Novartis's imatinib (Gleevec®) in 2001, and their success as cancer therapeutics, validate the trend ...

Physical activity is not only important for fitness but also for overall health. This is confirmed by a new study, which ...